Analyst Expectations for Rhythm Pharmaceuticals's Future
Portfolio Pulse from Benzinga Insights
Rhythm Pharmaceuticals (NASDAQ:RYTM) has received positive analyst ratings in the last quarter, with 2 bullish and 1 somewhat bullish rating in the last 30 days. Over the past 3 months, 4 analysts have set a 12-month price target for RYTM, with an average target of $39.00, a high of $45.00, and a low of $29.00. This average price target represents a 14.71% increase from the previous target of $34.00. Analyst ratings are opinions on stock performance and are updated quarterly.
December 07, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Rhythm Pharmaceuticals has seen a positive shift in analyst sentiment with an increased average price target of $39.00, suggesting a bullish outlook for the stock.
The recent analyst ratings for RYTM are predominantly bullish, with the average price target increasing by 14.71%. This positive sentiment is likely to influence investor perception and could lead to a short-term increase in the stock price, as price targets often act as a signal to the market about expected performance.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100